PHARMATEK · Hématologie

Assistant de documentation de l’ISS original de 2005 pour le myélome multiple

Documenter le stade ISS original et le détail de ses composantes à partir de résultats sériques préthérapeutiques complets et vérifiés de bêta-2-microglobuline et d’albumine.

Révision clinique en cours

La révision clinique doit être complétée.

Cet outil fait partie de la bibliothèque PharmaTek. Son calcul reste indisponible au public jusqu’à la validation de sa formule, de ses limites et de ses sources.

Explorer les outils accessibles

Sources, population et validation

État: clinical-review-pending
Version de la méthode: Greipp et al. original 2005 International Staging System (ISS), engine multiple-myeloma-iss-2005-v1: stage I requires serum beta-2 microglobulin <3.5 mg/L AND serum albumin >=3.5 g/dL; stage III requires serum beta-2 microglobulin >=5.5 mg/L irrespective of albumin; stage II is neither stage I nor stage III. Exact beta-2 microglobulin equality at 3.5 mg/L is not stage I, exact albumin equality at 3.5 g/dL meets the albumin stage-I component, and exact beta-2 microglobulin equality at 5.5 mg/L is stage III. The inclusive 5.5 mg/L boundary is locked to the original publication and is not changed by later summaries that print >5.5 mg/L. Serum albumin in g/L is normalized by g/dL = g/L / 10; serum beta-2 microglobulin is fixed to mg/L. Output is limited to stage I, II, or III, the three source-criterion booleans, and entered-value audit; no R-ISS, R2-ISS, genomic input, adjustment, or interpretation is supplied.
Population: Clinician-confirmed adults age 18 years or older with newly diagnosed, previously untreated symptomatic multiple myeloma for whom the original Greipp et al. 2005 ISS source context is independently established as applicable. The source study included 10,750 previously untreated patients with symptomatic multiple myeloma from 17 institutions in North America, Europe, and Asia, with baseline laboratory values obtained within one month before initial chemotherapy. This v1 app contract is deliberately stricter: serum beta-2 microglobulin and serum albumin must be verified measurements from the same baseline pretreatment serum assessment, with exact analyte identities and units confirmed.
Limites et exclusions: Use for diagnosis; MGUS; smouldering multiple myeloma; solitary plasmacytoma; AL amyloidosis without active symptomatic multiple myeloma; plasma-cell leukemia; relapsed or refractory disease; post-treatment restaging; or pediatric patients. · Measurements from different assessments, later or post-treatment results, urine beta-2 microglobulin, a non-serum albumin result, renal-adjusted or corrected values, missing, inferred, imputed, carried-forward, or default values, unsupported units, or unverified analyte or specimen identity. · R-ISS, R2-ISS, genomic staging, LDH, FISH or cytogenetic abnormalities, alternate thresholds, renal, inflammatory, or albumin adjustment, or any calculated-stage input. · Any risk label, survival or mortality estimate, probability, individual prognosis, diagnostic conclusion, treatment or transplant-eligibility statement, disposition, recommendation, or management decision.

Origine de l’outil PharmaTek

Outil importé de la bibliothèque PharmaTek de MDose. Aucune date de révision clinique indépendante n’est documentée dans cette version.

Bibliothèque source: PharmaTek · MDose
Version importée: 4b66536936ed
État de publication: Révision clinique en cours

POURSUIVRE AVEC MDOSE

Un outil. Un premier lien.

Recevez des nouvelles des outils ou discutez d’une collaboration. L’utilisation de PharmaTek reste accessible sans laisser vos coordonnées.

Médecins et partenaires